• Je něco špatně v tomto záznamu ?

Prognostic Factors for Survival in Glioblastoma: A Retrospective Analysis Focused on the Role of Hemoglobin

Z. Pleskacova, M. Bartos, H. Vosmikova, R. Dolezal, P. Krupa, B. Vitovcova, P. Kasparova, E. Rudolf, V. Skarkova, D. Pohankova, V. Novotna, J. Petera

. 2024 ; 12 (6) : . [pub] 20240529

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012683

Background: Although several prognostic factors for survival have been identified in glioblastoma, there are numerous other potential markers (such as hemoglobin) whose role has not yet been confirmed. The aim of this study was to evaluate a wide range of potential prognostic factors, including HIF-1α and hemoglobin levels, for survival in glioblastoma. A secondary aim was to determine whether hemoglobin levels were associated with HIF-1α expression. Methods: A retrospective study of 136 patients treated for glioblastoma at our institution between 2012 and 2021 was performed. Cox univariate and multivariate analyses were carried out. Kaplan-Meier survival curves were generated. In addition, bivariate non-parametric correlation analyses were performed for key variables. Results: Median survival was 11.9 months (range: 0-119.4). According to the univariate analysis, 13 variables were significantly associated with survival: age, performance status, extent of surgery, tumor depth, tumor size, epilepsy, postoperative chemoradiotherapy, IDH mutations, CD44, HIF-1α, HIF-1β, vimentin, and PDFGR. According to the multivariate regression analysis, only four variables remained significantly associated with survival: age, extent of surgery, epilepsy, and HIF-1α expression. No significant association was observed between hemoglobin levels (low <120 g/L in females or <140 g/L in males vs. high ≥120 or ≥140 g/L) and survival or HIF-1α/HIF-1β expression. Conclusions: In this retrospective study of patients with glioblastoma, four variables-age, extent of surgery, HIF-1α expression, and epilepsy-were significant prognostic factors for survival. Hemoglobin levels were not significantly associated with survival or HIF-1α expression. Although hypoxia is a well-recognized component of the glioblastoma microenvironment, more research is needed to understand the pathogenesis of onset tumor hypoxia and treatment implication.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012683
003      
CZ-PrNML
005      
20240726151341.0
007      
ta
008      
240723s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biomedicines12061210 $2 doi
035    __
$a (PubMed)38927417
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Pleskacova, Zuzana $u Department of Oncology and Radiotherapy, University Hospital and Medical Faculty, 500 05 Hradec Kralove, Czech Republic
245    10
$a Prognostic Factors for Survival in Glioblastoma: A Retrospective Analysis Focused on the Role of Hemoglobin / $c Z. Pleskacova, M. Bartos, H. Vosmikova, R. Dolezal, P. Krupa, B. Vitovcova, P. Kasparova, E. Rudolf, V. Skarkova, D. Pohankova, V. Novotna, J. Petera
520    9_
$a Background: Although several prognostic factors for survival have been identified in glioblastoma, there are numerous other potential markers (such as hemoglobin) whose role has not yet been confirmed. The aim of this study was to evaluate a wide range of potential prognostic factors, including HIF-1α and hemoglobin levels, for survival in glioblastoma. A secondary aim was to determine whether hemoglobin levels were associated with HIF-1α expression. Methods: A retrospective study of 136 patients treated for glioblastoma at our institution between 2012 and 2021 was performed. Cox univariate and multivariate analyses were carried out. Kaplan-Meier survival curves were generated. In addition, bivariate non-parametric correlation analyses were performed for key variables. Results: Median survival was 11.9 months (range: 0-119.4). According to the univariate analysis, 13 variables were significantly associated with survival: age, performance status, extent of surgery, tumor depth, tumor size, epilepsy, postoperative chemoradiotherapy, IDH mutations, CD44, HIF-1α, HIF-1β, vimentin, and PDFGR. According to the multivariate regression analysis, only four variables remained significantly associated with survival: age, extent of surgery, epilepsy, and HIF-1α expression. No significant association was observed between hemoglobin levels (low <120 g/L in females or <140 g/L in males vs. high ≥120 or ≥140 g/L) and survival or HIF-1α/HIF-1β expression. Conclusions: In this retrospective study of patients with glioblastoma, four variables-age, extent of surgery, HIF-1α expression, and epilepsy-were significant prognostic factors for survival. Hemoglobin levels were not significantly associated with survival or HIF-1α expression. Although hypoxia is a well-recognized component of the glioblastoma microenvironment, more research is needed to understand the pathogenesis of onset tumor hypoxia and treatment implication.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bartos, Michael $u Department of Neurosurgery, University Hospital and Medical Faculty, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Vosmikova, Hana $u The Fingerland Department of Pathology, University Hospital and Medical Faculty, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Dolezal, Rafael $u Biomedical Research Centre, University hospital and Medical Faculty, 500 05 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000194953934
700    1_
$a Krupa, Petr $u Department of Neurosurgery, University Hospital and Medical Faculty, 500 05 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000218327488 $7 xx0231389
700    1_
$a Vitovcova, Barbora $u Department of Medical Biology and Genetics, Medical Faculty, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Kasparova, Petra $u The Fingerland Department of Pathology, University Hospital and Medical Faculty, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Rudolf, Emil $u Department of Medical Biology and Genetics, Medical Faculty, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Skarkova, Veronika $u Department of Medical Biology and Genetics, Medical Faculty, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Pohankova, Denisa $u Department of Oncology and Radiotherapy, University Hospital and Medical Faculty, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Novotna, Veronika $u Department of Oncology and Radiotherapy, University Hospital and Medical Faculty, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Petera, Jiri $u Department of Oncology and Radiotherapy, University Hospital and Medical Faculty, 500 05 Hradec Kralove, Czech Republic
773    0_
$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 12, č. 6 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38927417 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151334 $b ABA008
999    __
$a ok $b bmc $g 2125444 $s 1224546
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 12 $c 6 $e 20240529 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Možnosti archivace